|
| Case | Ref. | P21 result | P21 location | P27 result | P27 location | P53 result | P53 location | EGF-R result | Bc12 result | Bc12 location | MIB-1% | MIB1 location | Other comments |
|
| 1 | Lin et al. [7] | + | Diffuse | + | Surface | − | | − | − | | 20 | Diffuse | |
|
| 2 | Lin et al. [7] | + | Diffuse | + | Diffuse | − | | − | − | | 15 | Diffuse | |
|
| 3 | Lin et al. [7] | + | Diffuse | − | | − | | − | − | | 35 | Diffuse | |
|
| 4 | Lin et al.[7] | + | Diffuse | + | Surface | − | | − | − | | 35 | Diffuse | |
|
| 5 | Lin et al. [7] | + | Base | + | Surface | + | Base | − | + | Surface | 2 | Base | |
|
| 6 | Lin et al. [7] | − | | + | Surface | − | | − | − | | 20 | Diffuse | |
|
| 7 | Lin et al. [7] | + | Base | + | Surface | − | | − | + | Surface | 35 | Diffuse | |
|
| 8 | Lin et al. [7] | + | Base | + | Surface | − | | − | − | | 15 | Base | |
|
| 9 | Lin et al. [7] | − | | + | Surface | + | Diffuse | − | − | | 30 | Diffuse | |
|
| 10 | Lin et al. [7] | + | Diffuse | + | Surface | − | | − | − | | 30 | Base | |
|
| 11 | Lin et al. [7] | + | Base | + | Surface | − | | − | − | | 20 | Diffuse | |
|
| 12 | Lin et al. [7] | + | Base | + | Surface | + | Base | − | − | | 15 | Base | |
|
| 13 | Wang et al. [11] | Not done | | Not done | | − | | Not done | Not done | | Not done | | |
|
| 14 | Tatsura et al. [12] | Not done | | Not done | | Not done | | Not done | Not done | | Not done | | Cytokeratin+ |
|
| 15 | Terada [13] | Not done | | | | + | | Not done | | | | | Ki-67 labeling = 15%; +cytokeratins; +EMA; α-methylacyl CoA racemase; +Ca19-9; MUC1 |
|
| 16 | Terada [13] | Not done | | Not done | | + | | Not done | | | | | Ki-67 labeling = 30%; +cytokeratins; +EMA, +p63, +p53, +C10, +CEA, +MUC1 |
|
| 17 | De Berardinis et al. [14] | Not done | | Not done | | Strongly+ | | Not done | | | | | Ki-67 +high expression |
|
| 18, 19, 20, 21, 22, 23, 24 | Cardillo et al. [15] (7 cases) | Not done | | Not done | | Not done | | Not done | | | | | |
|
| 25 | Dundar et al. [16] | Not done | |
+40% | | +40% | | Not done | | | | | Ki-67 20%; 34βE12; −PSA; −AE1 |
|
| 26 | Dundar et al. [16] | Not done | | +50% | | +40% | | | | | | | Ki-67 15%; +34βE12; −PSA; −AE1 |
|
| 27 | Badoual et al. [17] | Details not available | Details not available | Details not available | Details not available | Details not available | Details not available | Details not available | Details not available | Details not available | Details not available | Details not available | Details not available |
|
| 28 | Badoual et al. [17] | Details not available | Details not available | Details not available | Details not available | Details not available | Details not available | Details not available | Details not available | Details not available | Details not available | Details not available | Details not available |
|
| 29 | Krishnamoorthy et al. [18] | Details not available | Details not available | Details not available | Details not available | Details not available | Details not available | Details not available | Details not available | Details not available | Details not available | Details not available | Irregular nests of tubules in lamina propria |
|
| 30. | Ozdemir et al. [19] | Not done | | Not done | | Not done | | Not done | | | | Not done | Details not available to author |
|
| 31 |
Holmäng and Johansson [20] | Details not available to author | Deatials not available to author | Deatials not available to author | Deatials not available to author | Deatials not available to author | Deatials not available to author | Deatials not available to author | Deatials not available to author | Deatials not available to author | Deatials not available to author | Deatials not available to author | |
|
| 32 | Ooi et al. [21] | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | |
|
| 33 to 86 | Linder et al. [22] | 52 patients | Details not availabe | Details not availabe | Details not availabe | Details not availabe | Details not availabe | Details not availabe | Details not availabe | Details not availabe | Details not availabe | Details not availabe | |
|
| 87 | Tripodi et al. [23] | Not done | | Not done | | Not done | | | | | | | +P63 |
|
| 88 | Cerda et al. [24] | Not done | | Not done | | Not done | Not done | Not done | Not done | Not done | Not done | | +CK7,+CK20,
+34βE12, +P63 |
|
| 89 | Cerda et al. [24] | Not done | Not done | Not done | Not done | Not done | Not done | Not done | Not done | Not done | Not done | | +CK7,+CK20, +34βE12, +P63 |
|
| 90 |
Yildiz et al. [25] | Details unavailable | | Details unavailable | | Details unavailable | | Details unavailable | | Details unavailable | | Details unavailable | |
|
| 91 |
Pusztaszeri et al. [26] | Details not available to author | | Details not available to author | | Details not available to author | | Details not available to author | | Details not available to author | Details not available to author | Details not available to author | |
|
| 92 | Lau [27] | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | |
|
| 93 | Stern [1] | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | |
|
| 94–96 | Talbert and Young [3] | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | |
|
| 97–100 | Murphy and Deana [4] | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | |
|
| 101–130 | Wasco et al. [8] | | | | | | | | | | | | CK7+ (93%); CK20+ (68%); P63+ (92%); CK903+ (92%) |
|
| 131–134 | Young and Oliva [9] | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | |
|
| 135–150 | Drew et al. [10] | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | |
|
| 151 and 152 | Xiao et al. [28] | | | | | High +p53 | | | | | | | Both Strongly+ for 63;
and High Ki-67 indices
Case 1
+CK 903;
+CK7
+CK20;
−PSA; −prostatic acid phosphatase;
Strongly +p63;
+p53 40% to 50%;
+Ki-6730 to
Case 2
+CK903;
+CK7;
−PSA;
−prostatic acid phosphatase;
−S100;
−chromogranin;
+p63 30 to 40%;
Focally +p53;
Focally +Ki-67 |
|
| 153 | Huang et al. [29] | | | | | | | | | | | | +CK7;
+CK20;
+thrombomodulin;
+34βE12 |
|
| 154–164 | Volmar et al. [30] | | | | | | | | | | 8.8% | | +p53 4.2%;
+P27 4.7%; |
|
| 165–174 |
Holmäng and Johansson [20] 10 cases | Details not available | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | |
|
| 175–177 | Liedberg et al. [31] | Details not available | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | |
|
| 178–200 | Cox and Epstein [32] | Details not available | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | |
|
